Sarah Boyce is the President and Chief Executive Officer at Avidity Biosciences Inc., a biotechnology company focused on developing innovative RNA therapeutics. With an extensive background in the life sciences industry, Boyce brings a wealth of experience and expertise to her role. Prior to joining Avidity Biosciences, she held several leadership positions at notable companies, including serving as the Chief Operating Officer at Repertoire Immune Medicines and President and Chief Executive Officer at Translate Bio. Throughout her career, Boyce has demonstrated a strong track record of driving growth and innovation in the biotechnology sector. At Translate Bio, she played a pivotal role in advancing the company's mRNA platform and securing strategic partnerships, which ultimately led to the company's acquisition by Sanofi. Her leadership skills and strategic vision have been instrumental in guiding Avidity Biosciences through its various stages of development, from early-stage research to clinical trials. As President and CEO of Avidity Biosciences, Sarah Boyce is responsible for overseeing the company's overall strategy and operations. Under her leadership, the company is working to advance its Antibody Oligonucleotide Conjugate (AOC) platform, which has the potential to treat a wide range of diseases. Boyce's dedication to improving patient outcomes and her ability to foster a collaborative and innovative work environment have positioned Avidity Biosciences as a leader in the field of RNA therapeutics.